Mandeep Singh
Interventional cardiologist and professor of medicine at Mayo Clinic; corresponding author on a 2026 trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF)
Mayo Clinic College of Medicine and Science · Rochester, MN
Mayo Clinic, Department of Cardiovascular Diseases (Rochester, Minnesota, USA) ↗ ORCID0000-0002-9750-746X ↗
Mandeep Singh is a professor of medicine and interventional cardiologist in the Department of Cardiovascular Diseases at Mayo Clinic, Rochester, where he trained as an interventional cardiology fellow in the late 1990s.
In 2026 he was the corresponding author on a trial testing rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF), working alongside aging researchers James Kirkland (Mayo's Robert and Arlene Kogod Center on Aging) and Dudley Lamming (University of Wisconsin-Madison).
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Rapamycin in Frail Older Subjects with Heart Failure with Preserved Ejection Fraction LAN2026 Corresponding author on a trial of low-dose rapamycin in frail older HFpEF patients. |
Co-authors in the Atlas
People with a profile here who share at least one study with Mandeep Singh.
- Dudley W. Lamming Showed as a postdoc that rapamycin's harm to glucose metabolism comes largely from its effect on mTORC2, while the lifespan benefit tracks mTORC1. His Wisconsin lab studies intermittent rapamycin dosing and how restricting dietary protein or single amino acids affects metabolism and ageing